New Drug Approved For ALS
Diane S. Aschenbrenner
Abstract
Sodium phenylbutyrate-taurursodiol (Relyvrio) has been approved to treat amyotrophic lateral sclerosis.The drug was approved despite the absence of phase 3 clinical trial data. Data from a small phase 2 trial indicated that patients receiving Relyvrio had a slower loss of functioning than those taking placebo.Relyvrio poses a risk to patients who are sensitive to salt intake and to those with pancreatic, intestinal, and enterohepatic circulation disorders.
Topics & Concepts
MedicinePlaceboDrugInternal medicineClinical trialAmyotrophic lateral sclerosisGastroenterologyPharmacologyAlternative medicinePathologyDiseaseNeurogenetic and Muscular Disorders ResearchGenetics and Neurodevelopmental DisordersAutism Spectrum Disorder Research